Popular Hepatitis News and Current Events

Popular Hepatitis News and Current Events, Hepatitis News Articles.
Sort By: Most Relevant | Most Recent
Page 1 of 25 | 1000 Results
A foodborne illness outbreak could cost a restaurant millions, study suggests
A single foodborne outbreak could cost a restaurant millions of dollars in lost revenue, fines, lawsuits, legal fees, insurance premium increases, inspection costs and staff retraining, a new study from researchers at the Johns Hopkins Bloomberg School of Public Health suggests. (2018-04-16)

Morris Animal Foundation study identifies new virus in cat
Morris Animal Foundation-funded researchers from the University of Sydney have found a previously undiscovered hepadnavirus in an immunocompromised cat, and subsequently in banked samples. The research team published their results today in the prestigious journal Viruses. (2018-05-17)

Icelandic program seeks to eliminate HCV
A new Journal of Internal Medicine study describes an innovative program to eliminate hepatitis C virus (HCV) as a public health threat in Iceland. (2018-03-07)

Hepatitis C: A novel point-of-care assay
One of the major challenges identified by the WHO in efforts to eradicate the hepatitis C virus is the diagnosis of chronic cases that are generally asymptomatic. Major progress is required for new diagnostic techniques that can be 'decentralized,' in other words accessed by populations and countries with limited resources. Scientists from the Institut Pasteur and Inserm, in collaboration with the company genedrive, have developed and validated a rapid, reliable, point-of-care HCV assay. (2018-04-10)

Hepatitis C virus screening rates remain low among baby boomers
Despite the steady increase of liver cancer incidence in the United States in recent decades, data from 2015 indicates that less than 13 percent of individuals born between 1945 and 1965 are estimated to have undergone screening for hepatitis C virus (HCV). (2018-03-27)

How to select anti-hepatitis B virus agents for drug-resistance patients?
Chronic hepatitis B virus (HBV) infection remains a global public health problem. Nucleoside analogs play an important role in antiviral therapy for chronic hepatitis B patients. However, many patients with a certain nucleoside analogs therapy for a period of time may be resistant to this antiviral agent. This article described a useful strategy to select anti-HBV agents for drug-resistance patients. (2008-09-24)

Screening for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis achieving sustained virological response is likely to be cost effective
A Canadian study suggests that biannual or annual ultrasound screening for HCC is likely to be cost effective after a sustained virological response in those with hepatitis C-related cirrhosis, but not in those with advanced fibrosis without cirrhosis. (2018-04-12)

Vitamin D deficiency common in patients with IBD, chronic liver disease
The 73rd Annual Scientific Meeting of the American College of Gastroenterology in Orlando found patients with inflammatory bowel disease or chronic liver disease were at increased risk of developing Vitamin D deficiencies. Two separate studies highlight the importance of regular Vitamin D checkups in the evaluation of patients with certain digestive diseases. (2008-10-06)

HEPAHEALTH Project Report -- risk factors and the burden of liver disease in Europe and selected Central Asian countries
The HEPAHEALTH Project Report, which was presented today in a press conference at The International Liver Congress trade; 2018 in Paris, France, is the second overview commissioned by EASL on the burden of liver disease in Europe. (2018-04-12)

Nano vaccine for hepatitis B shows promise for third world
A new needle-less vaccine is highly effective and can be stored without refrigeration, University of Michigan studies in animals show. The vaccine should also be safer to administer than existing hepatitis B vaccines and effective with only two immunizations. The technique, a nanoemulsion given in the nose, is a step closer to human trials, possibly within a year. Hepatitis B kills an estimated 1 million people annually. (2008-08-12)

HCV-related liver transplantation and post-transplant survival rates in Europe have improved rapidly in the era of direct-acting antiviral drugs
HCV-related liver transplantation and post-transplant survival rates in Europe have improved rapidly in the era of direct-acting antiviral drugs. (2018-04-13)

Linkage to care specialist facilitates access to hepatitis C treatment for people who inject drugs
A longitudinal study involving more than 1,000 individuals reports promising role for linkage to care specialists in expanding access to hepatitis C treatment for people who inject drugs. (2018-04-12)

Study concludes no racial disparities in long-term outcomes in recipients of liver transplants
New research published in the Journal of the American College of Surgeons shows long-term survival and liver rejection rates are equivalent for African-American liver transplant patients as compared with patients of other races. The study also suggests that although other factors such as liver cancer or hepatitis may negatively influence long-term survival, race does not. (2008-05-19)

Hepatitis therapy: Kupffer cells adjust the balance between pathogen control and hepatocyte regenera
Scientists from TWINCORE have now published new insights on the processes involved in liver inflammation in the Journal of Hepatology: Type I interferons, on the one hand, limit viral replication and thereby help the immune cells to control the viral pathogen. On the other hand, type I interferons delay the regeneration of immune cells, which are important to adjust and maintain the immune balance within the liver during acute inflammation. (2018-01-17)

Hepatitis C virus elimination programmes report encouraging results: Is elimination within reach?
ILC 2018: National programmes in Georgia and Iceland report high levels of engagement, treatment initiation, and cure, suggesting HCV elimination targets are achievable. (2018-04-13)

A new protocol for Hepatitis A vaccination to prevent a vaccine-resistant virus
Researchers of the University of Barcelona (UB) have analysed, with massive sequencing techniques for the first time, the evolution of the Hepatitis A virus with samples from patients. The results, published in the journal EBioMedicine, show the presence of variants of the virus that could escape the effects of the vaccine. (2019-02-08)

New affordable hepatitis C combination treatment shows 97 percent cure rate
The sofosbuvir/ravidasvir combination treatment for hepatitis C has been shown to be safe and effective, with extremely high cure rates, according to interim results from the Phase II/III STORM-C-1 trial presented by DNDi at the International Liver Conference in Paris. (2018-04-12)

The risk factors of idiopathic pulmonary fibrosis in HCV patients
A group from Toranomon Hospital of Japan investigated the cumulative development incidence and predictive factors for idiopathic pulmonary fibrosis in HCV positive patients. They found that age, smoking and liver cirrhosis enhance the development of idiopathic pulmonary fibrosis in HCV positive patients. (2008-10-23)

Sustained virological response to oral hepatitis C virus treatment associated with reduced mortality in an Italian cohort
A large-scale, real-world data on the course of liver disease after clearance of HCV with direct-acting antiviral agents show reduced risk of death at all stages of disease. (2018-04-13)

'Exciting' discovery on path to develop new type of vaccine to treat global viruses
Scientists at the University of Southampton have made a significant discovery in efforts to develop a vaccine against Zika, dengue and Hepatitis C viruses that affect millions of people around the world. (2017-09-15)

Discovery of new Hepatitis C virus mechanism
Researchers at Osaka University, Japan uncovered the mechanisms that suppress the propagation of the hepatitis C virus with the potential of improving pathological liver conditions. Using model mice, they confirmed that when a certain enzyme is inhibited, HCV particle production is reduced leading to an improvement of pathological liver conditions. They thereby identified a new drug target for the development of new HCV drugs. (2016-07-27)

New MRI tech could help doctors detect heart disease with better accuracy
Doctors might be able to better detect any disease or disorder that involves inflammation thanks to a new MRI imaging technology co-developed by faculty at Binghamton University, State University of New York. (2017-12-13)

Insurance denials for new hepatitis C drugs remain high nationwide, study suggests
Highly effective drugs that can cure chronic hepatitis C infection in approximately 95 percent of patients first became available in the US in 2014. But both public and private insurers continue to deny coverage for these costly drugs at high rates nationwide, despite efforts to remove treatment restrictions, according to a new study published in Open Forum Infectious Diseases. (2018-06-07)

Organ-on-chip technology enters next stage as experts test hepatitis B virus
Scientists at Imperial College London have become the first in the world to test how pathogens interact with artificial human organs. (2018-02-14)

Hepatitis C virus may need enzyme's help to cause liver disease
A key enzyme may explain how hepatitis C infection leads to serious liver diseases, reports the University of Pittsburgh Graduate School of Public Health. The study, to be published in the July 9 online issue of Hepatology, shows that fatty acid synthase is highly elevated in human liver cells exposed to the hepatitis C virus, suggesting that testing enzyme levels could help predict more serious, long-lasting health consequences from hepatitis C. (2008-07-09)

The positive and negative role of LRH-1 during inflammation
The research group around Professor Thomas Brunner at the University of Konstanz discovers the role that the LRH-1 protein plays in the immune system -- inhibiting this protein could help treat inflammatory diseases. (2019-07-25)

New test allows for one-step diagnosis of HCV infection
The current standard in diagnosing Hepatitis C virus (HCV) infection requires two sequential steps that make it suboptimal, costly, inconvenient, time consuming, and globally not widely available or affordable. Now researchers have developed a novel enzyme immunoassay that accomplishes screening and diagnosis in one simple and affordable step. (2016-06-07)

Could the biological clock be a key ally in the fight against inflammatory disease?
What if the symptoms and seriousness of certain inflammatory diseases were linked to time of day? Researchers from Inserm have been working on this hypothesis, after noting that the seriousness and mortality associated with fulminant hepatitis were dependent on the time at which the disease was induced. Their study, conducted on human cells and mice, shows that the anti-inflammatory action of a biological clock protein could prevent the onset of fulminant hepatitis, by alleviating symptoms and increasing survival rates. (2018-01-26)

How viruses disarm the immune system
How do viruses that cause chronic infections, such as HIV or hepatitis c virus, manage to outsmart their hosts' immune systems? The answer to that question has long eluded scientists, but new research from McGill University has uncovered a molecular mechanism that may be a key piece of the puzzle. The discovery could provide new targets for treating a wide range of diseases. (2018-02-05)

Study finds racial differences in cure rates for Hepatitis C
In a large ethnically diverse group of patients seen at a community-based Veterans Affairs practice, cure rates for chronic hepatitis C were lower for African American individuals relative to White individuals, even when patients were receiving optimal therapies. The findings are published in Pharmacology Research & Perspectives. (2018-02-22)

Punjab, India: Mass treatment of a population with chronic hepatitis C infection produces high rates of cure
A program of decentralized public healthcare achieves high rates of cure regardless of genotype or the presence of cirrhosis: the Punjab Model. (2018-04-12)

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases. This study, which used survey and vital statistics data, suggests about 1 percent of adults (0.93 percent) were living with hepatitis C from 2013 to 2016, and how common infections were varied by state and region. (2018-12-21)

Counterattack of the hepatitis B virus
The hepatitis B virus (HBV) infects liver cells. Drugs are available to treat HBV, but they rarely cure the infection, and so the virus typically returns after the treatment ends. A team led by researchers from UNIGE discovered how our cells defend themselves against HBV infection, but also how the virus fights back. This work represents an important advance in our understanding of HBV and suggests new avenues for the development of innovative therapeutic agents. (2016-03-16)

Who found some new mechanisms of HBV virulence?
Despite the existence of safe and efficient vaccines, hepatitis B virus is one of the most deadly viruses in the world, killing about 1.2 million people every year. To better understand the direct liver disease induced by hepatitis B virus, recent research led by Dr. Kremsdorf from the French National Institute of Health and Medical Research brought us one step closer to an effective treatment for HBV infection. (2008-02-22)

National Academies target opioid abuse and infectious disease consequences
The National Academies of Sciences, Engineering, and Medicine today released proceedings of a March 12 workshop exploring the rise in infectious diseases accompanying opioid abuse, and possible strategies for reducing both epidemics. (2018-07-13)

First real-world studies report glecaprevir/pibrentasvir to be effective and well tolerated in chronic HCV infection
Studies conducted in Italy and Germany confirm the effectiveness and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection, with viral suppression rates similar to those observed in clinical trials. (2018-04-12)

Global burden of disease study focuses on liver cancer
A new article published by JAMA Oncology reports the results of the Global Burden of Disease 2015 study on primary liver cancer incidence, death and years of healthy life lost in 195 countries or territories from 1990 to 2015. (2017-10-05)

Cough virus kills liver cancer cells and hepatitis virus
A virus that causes childhood coughs and colds could help in the fight against primary liver cancer, according to a study. Reovirus stimulates the body's own immune system to kill off the cancerous cells, the researchers at the University of Leeds found. (2016-11-15)

Cancer stem cells, allies of the tumor and enemies of the patient
Research results point to a therapeutic value for the protein (Ahr) because controlling it might repress the pluripotency of the cancer stem cell and reduce the malignity of the tumour. Indeed, different naturally-occurring molecules have been identified that modulate the activity of this protein in specific ways. In addition, the dioxin receptor might also facilitate the development of tools for the prognosis and evolution of the types of cancer in the study, hepatocellular carcinoma and melanoma. (2018-03-05)

WHO guidelines fail to detect half of chronic hepatitis B patients in Ethiopia needing treatment
Current World Health Organization (WHO) guidelines for chronic hepatitis B (CHB) fail to detect half of the patients in need of treatment in Ethiopia, report scientists in the Journal of Hepatology, published by Elsevier. They propose revision of the guidelines to consider local data from sub-Saharan Africa in order to help reach the WHO goal of eliminating viral hepatitis as a major public health threat by 2030. (2019-03-28)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.